Topical Delivery of Apremilast Loaded Nanostructured Lipid Carrier Based Hydrogel for Psoriasis Therapy

Background: Apremilast (APR) is an orally administered selective phosphodiesterase 4 inhibitor approved to treat plaque psoriasis and psoriatic arthritis available as oral tablet formulation. However, its systemic side effects limit application. The low solubility permeability of apremilast make it difficult administer through the skin. Hence attempt made incorporate into a suitable nanocarrier facilitate topical delivery.
 Aims: To formulate characterize loaded nanostructured lipid carriers for management reduce effects.
 Methodology: Nanostructured Lipid (NLC) were prepared by melt emulsification accompanied probe sonication. formulation was using GMS, Sefsol 218, Tween 80 Transcutol P Solid Lipid, Liquid lipid, Surfactant Penetration Enhancer. NLC incorporated carbapol 934 dispersion convert gel. evaluated size, Polydispersity Index, Zeta Potential, Entrapment efficiency, Transmission Electron Microscopy. After that, gel examined Spreadability, Extrudabilty, Viscosity, In vitro drug release, Ex vivo permeation, Skin deposition studies.
 Results: formulated showed particle size less than 200 nm (i.e.170.32nm) with narrow PDI 0.267. efficiency revealed that 89.26±01.22% entrapped. electron microscopy images confirmed spherical nature nanocarrier. extended-release pattern 24h observed in release studies followed Higuchi model(R2=0.9966). 6.14 fold increase 74.05±0.25% compared stable three months without significant changes. skin did not have any irritation potential. antipsoriatic activity demonstrated imiquimod induced model mice comparable standard treatment.
 Conclusion: enhanced improved retention conventional developed can be alternative therapy after clinical trials future.